Top journals have published articles: Can this vaccine protect the new crown variant with just one shot?

Today, a paper published in the journal Nature introduced the latest developments in a new crown vaccine

This vaccine was developed by Johnson & Johnson and was authorized by the US FDA for emergency use a few months ago

The first is the level of neutralizing antibodies produced by the vaccine

But in addition to neutralizing antibodies, non-neutralizing antibody reactions and T cell reactions are almost unaffected by mutant viruses

In addition, whether it is an unmutated new coronavirus, or an alpha variant (originally discovered in the UK), a beta variant, and a gamma variant, the CD8 and CD4 T cell responses in the volunteers are all at the same level

Some people may ask, are these results worth referring to? In the real world, can immune responses other than neutralizing antibodies also provide adequate protection for vaccinators? A paper in the New England Journal of Medicine earlier this year answered this question

It was found that the vaccine group outperformed the placebo control group

The conclusion of the paper pointed out that Johnson & Johnson's single-dose vaccine has shown safety and effectiveness in combating symptomatic new coronary diseases

▲The mechanism of action of this vaccine (picture source: reference [2])

A Harvard University press release today mentioned that based on the protective effect in the Phase 3 clinical trial, the non-neutralizing antibody response and T cell response shown in the "Nature" paper may play a protective role against the new crown disease

"The current vaccine is designed for the original strain of the new coronavirus at the beginning of the epidemic

Note: The original text has been deleted

Reference materials:

[1] Alter, G.

[2] Jerald Sadoff et al.

[3] Single-shot COVID-19 vaccine generates robust immune responses against variants, Retrieved June 9, 2021, from https://news.